Biocon’s Malaysia Insulin Plant Wins EU Clearance, Company Is Open To PE Investment

Biocon has received European regulatory clearance for its new Malaysian insulin plant and also said it is open to private-equity investment proposals for its fast-growing biologics division ahead of a planned IPO.

EU_Malaysia_Flags
Biocon has good European clearance for its insulins facility in Malaysia • Source: Shutterstock

Biocon’s new Malaysian plant, where the Indian biotech heavyweight is making its insulin biosimilar that is a challenger to Sanofi’s blockbuster Lantus, has cleared a key regulatory hurdle. The facility, Asia’s largest integrated insulins plant, has received a certificate of good manufacturing practice from European regulators that Biocon said will help the company supply the EU diabetes market “even more aggressively.”

Biocon founder and chief executive Kiran Mazumdar-Shaw also said she is open to private-equity investment ahead of the firm’s planned...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin